Physician profile
Robert Wirick
NPI 1710688460
$1,563.40
in general payments reported to CMS, 2019-2025
18 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $181 · 2024: $955 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.56 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $398.24 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $254.75 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.93 | 2024-2025 | Caplyta |
| Tris Pharma INC | $96.34 | 2024-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $92.06 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $85.34 | 2023-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $70.89 | 2024 | Ingrezza |
| Abbvie INC. | $67.57 | 2024-2025 | |
| Corium, LLC | $66.65 | 2023-2024 | Azstarys |
| Orexo US, INC. | $39.70 | 2024 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $37.33 | 2024-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $29.04 | 2024 | Fanapt |
| Indivior INC. | $23.92 | 2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $22.15 | 2024 | |
| Braeburn INC. | $21.97 | 2024 | Brixadi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.24 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $16.64 | 2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wirick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.